LAWRENCE, Mass., Dec. 7, 2017 /PRNewswire/ -- NxStage Medical, Inc. (Nasdaq: NXTM), a leading medical technology company focused on advancing renal care, today announced new results in Hemodialysis International, demonstrating its remote patient management system, Nx2me Connected Health, reduces home hemodialysis technique failure, or conversion to in-center hemodialysis, by 29%.1
In the study, outcomes among 606 Nx2me users and contemporary matched controls were compared.1 Nx2me users comprised both patients already established on home hemodialysis with the NxStage System One and new home hemodialysis patients. In patients who began to use Nx2me within 3 months after initiating home hemodialysis, technique failure was reduced by 34%, relative to matched controls.1 Additionally, patients who began to use Nx2me during home hemodialysis training were 61% more likely to complete training and did so in 7 fewer days, relative to matched controls.1
A key component of the Nx2me platform is the Nx2me iPad® app, which is designed to increase patients' ease of use of home therapy by capturing treatment data and wirelessly sending it to their center after each treatment, thereby reducing the need for paper flow sheets. Dialysis center staff can access the treatment data, sent through a secured and encrypted web server, using the Nx2me Clinician Portal. The timely receipt of electronic flowsheets from the Nx2me app allows for early intervention to help reduce patient complications and hospitalizations. In addition, Nx2me integrates with center EMR systems to provide clinicians with treatment and billing information.
"Nx2me provides the tools to support and proactively engage with patients," said, Eric Weinhandl, Clinical Epidemiologist and Statistician, NxStage Medical, Inc. "Nx2me enhances dialysis care for both patients and center staff, and the performance data continue to demonstrate improved training graduation and patient retention, which both help to grow home hemodialysis."
For more information about Nx2me and home hemodialysis with the NxStage System One, please visit www.NxStage.com.
The NxStage System One is a prescription device and, like all medical devices, involves some risks. The risks associated with hemodialysis treatments in any environment include, but are not limited to, high blood pressure, fluid overload, low blood pressure, heart-related issues, and vascular access complications. The medical devices used in hemodialysis therapies may add additional risks including air entering the bloodstream, and blood loss due to clotting or accidental disconnection of the blood tubing set. Certain risks are unique to the home. Treatments at home are done without the presence of medical personnel and on-site technical support. Patients and their partners must be trained on what to do and how to get medical or technical help if needed. Patients should consult with their doctor to understand the risks and responsibilities of home and/or more frequent hemodialysis using the NxStage System One. Additionally, the reported benefits of home and/or more frequent hemodialysis may not be experienced by all patients.
The Nx2me Connected Health System is not intended to provide time sensitive data or alarms and does not control the System One Cycler. The system may not be used as a substitute for direct medical intervention or emergency care.
About the NxStage System One
The NxStage System One is the first and only truly portable hemodialysis system cleared specifically by the FDA for home hemodialysis, home nocturnal hemodialysis and solo home hemodialysis. Its simplicity and revolutionary size (just over a foot tall) are intended to allow convenient use in patients' homes and give patients the freedom to travel with their therapy. When combined with the NxStage PureFlow SL Dialysis Preparation System, patients are able to further simplify, using ordinary tap water to create dialysis fluid on demand. Unlike conventional hemodialysis systems, the System One requires no special infrastructure to operate. Under the guidance of their physician, patients can use the NxStage System One, with their trained partners (or for patients prescribed to receive solo dialysis, alone), where, how and when it best meets their needs, including while they are sleeping - at home or on vacation and at a medically appropriate treatment frequency. In addition, NxStage's Nx2me Connected Health platform collects important NxStage System One and patient information for flexible viewing, monitoring and reporting that may improve patient management and patient retention, as well as simplify alternative site care. www.nxstage.com.
About NxStage Medical
NxStage Medical, Inc. (Nasdaq: NXTM) is a leading medical technology company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment of ESRD and acute kidney failure. NxStage also has established a small number of dialysis clinics committed to the development of innovative care delivery models for patients with ESRD. For more information on NxStage and its products and services, please visit the Company's websites at www.nxstage.com and www.nxstagekidneycare.com.
This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors including those that are discussed in NxStage's filings with the Securities and Exchange Commission, including its Quarterly Report on Form 10-Q for the quarter ended September 30, 2017. NxStage is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
References: 1. Weinhandl ED, Collins AJ. Relative risk of home hemodialysis attrition in patients using a telehealth platform. Hemodial Int. 2017. http://onlinelibrary.wiley.com/doi/10.1111/hdi.12621/full
SOURCE NxStage Medical, Inc.